Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer

NCT00378703 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

361

Enrollment

NIH

Sponsor class

Conditions

Clear Cell Renal Cell Carcinoma
Recurrent Renal Cell Carcinoma
Stage IV Renal Cell Cancer AJCC v7

Interventions

BIOLOGICAL: Bevacizumab
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study
DRUG: Sorafenib Tosylate
DRUG: Temsirolimus

Sponsor

National Cancer Institute (NCI)